Ligand Pharmaceuticals Incorpor (LGND) Stock Analysis
Healthcare · Biotechnology
Wait for pullback to $200.18. At $223.56 the A.R:R is 0.1:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $200.18 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Supplier: Hovione; Analyst target reached - limited upside remaining.
Ligand Pharmaceuticals is a biopharmaceutical royalty company that acquires royalty streams from commercial and development-stage medicines, supplemented by its Captisol platform technology for drug solubility enhancement. Revenue comes from royalties on partner drug sales... Read more
Wait for pullback to $200.18. At $223.56 the A.R:R is 0.1:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $200.18 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Supplier: Hovione; Analyst target reached - limited upside remaining. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. | News modifier +1 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Score 6.0/10, moderate confidence.
Passes 5/8 gates (clean insider activity, no SEC red flags, news boost earnings 0.70, news boost analyst 0.70, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 7d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierHovione10-K Item 1A: 'We obtain Captisol from Hovione, our third-party manufacturer, primarily at their facilities in Ireland and Portugal.'
- MEDIUMProductKyprolis10-K Item 1A: 'A significant portion of our royalty revenue is based on sales of Kyprolis by Amgen'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·1 ceiling hit
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $200.18. At $223.56 the A.R:R is 0.1:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $200.18 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Supplier: Hovione; Analyst target reached - limited upside remaining. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. | News modifier +1 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Target $226.11 (+1.1%), stop $178.65 (−25.1%), Setup A.R:R 2.3:1. Score 6.0/10, moderate confidence.
Take-profit target: $226.11 (+13.0% upside). Target $226.11 (+1.1%), stop $178.65 (−25.1%), Setup A.R:R 2.3:1. Stop-loss: $178.65.
Concentration risk — Supplier: Hovione; Analyst target reached - limited upside remaining; Earnings in 7 days (event risk).
Ligand Pharmaceuticals Incorpor trades at a P/E of 36.7 (forward 19.6). TrendMatrix value score: 5.6/10. Verdict: Buy (Wait for Entry).
15 analysts cover LGND with a consensus score of 4.3/5. Average price target: $260.
What does Ligand Pharmaceuticals Incorpor do?Ligand Pharmaceuticals is a biopharmaceutical royalty company that acquires royalty streams from commercial and...
Ligand Pharmaceuticals is a biopharmaceutical royalty company that acquires royalty streams from commercial and development-stage medicines, supplemented by its Captisol platform technology for drug solubility enhancement. Revenue comes from royalties on partner drug sales (including Kyprolis by Amgen) and Captisol material sales, with Captisol sales to partners including Amgen representing approximately half of royalty revenues. It holds royalties across more than 15 marketed products.